Question 1

What is quality management software for regulated industries?

Accepted Answer

Quality management software supports GxP-regulated quality operations: document control, deviations, CAPA, change control, audit management, training, and supplier management. In pharma and medical device contexts, it overlaps with submission-related quality work: CMC quality documentation, 21 CFR Part 11 compliance, inspection readiness. Assyro's quality capability focuses on the submission-adjacent quality work (evidence traceability, inspection preparation, 483 response drafting) rather than shop-floor GMP operations which are typically handled by dedicated QMS platforms.

Question 2

How is Assyro different from Veeva QualityOne or MasterControl?

Accepted Answer

Veeva QualityOne and MasterControl are comprehensive QMS platforms with deep GMP operational support: batch records, deviations, CAPA, training. Assyro is submission-focused and quality-adjacent: it handles the quality documentation that becomes part of regulatory submissions and the inspection readiness workflow, but it is not a full GMP QMS. Most pharma and device organizations need both: a dedicated QMS for GMP operations, and submission software (like Assyro) for regulatory filings. The two complement rather than compete.

Question 3

Can Assyro integrate with our existing QMS?

Accepted Answer

Yes. Common integration patterns: Veeva QualityOne, MasterControl, TrackWise, TrackWise Digital. Quality events (deviations, CAPAs, change controls) logged in the QMS can surface in Assyro when they're relevant to active submissions, and submission-triggered quality activities (new PAS requiring CAPA on process change) can create tasks in the QMS. The goal is to avoid the double-entry pattern where quality and regulatory teams maintain separate records of the same underlying event.

Question 4

How does Assyro help with FDA inspection readiness?

Accepted Answer

Inspection readiness in Assyro is not a separate mode — it's a natural consequence of running operations in the platform. Every action logs with user, timestamp, and rationale; every document has full version history; every decision links to supporting evidence. When FDA schedules a PAI, the inspection package is retrievable in hours rather than compiled over weeks. Specific inspection-preparation workflows (pre-inspection mock audits, evidence gap analysis, 483 preparation) are supported directly.

Question 5

Does Assyro support 483 and Warning Letter response drafting?

Accepted Answer

Yes. 483 observations and Warning Letter citations drive structured response workflows: observation analysis, root cause documentation, CAPA development, evidence of correction, and response letter drafting. AI-assisted drafting pulls precedent from prior similar observations (within your organization's history and, where applicable, public FDA Warning Letter content) to accelerate first-draft generation. Quality and regulatory teams collaborate on the response in the same workspace rather than passing drafts across email.

Question 6

Can Assyro handle data integrity expectations?

Accepted Answer

Yes. FDA and EMA data integrity expectations (ALCOA+, audit trail review, computer system validation) apply to submission work directly. Assyro's audit trail, electronic signature support, and access controls align with 21 CFR Part 11 and EU Annex 11 expectations. For quality teams concerned about data integrity in submission-related activities, the platform provides the controls and evidence to demonstrate compliance during inspection.

Question 7

How does Assyro support multi-site quality operations?

Accepted Answer

Global quality organizations typically manage operations across multiple manufacturing sites and multiple regulatory regions. Assyro's site-scoped workflows let each site operate within the global quality framework while preserving site-level accountability. Quality status rolls up across sites for leadership visibility. Site-specific inspection preparation (FDA at US site, EMA at EU site) uses the same underlying evidence infrastructure with region-specific regulatory framing.

Question 8

What about ICH Q12 and lifecycle quality management?

Accepted Answer

ICH Q12 introduced formal lifecycle management concepts for CMC changes: Established Conditions, Post-Approval Change Management Protocols, and the regulatory flexibility that comes with validated quality systems. Assyro supports Q12 workflows including EC documentation, PACMP authoring, and the quality evidence that supports PACMP-covered changes. For sponsors adopting Q12 lifecycle strategies, the quality team's role becomes more integral to submission strategy, which Assyro's integrated quality-and-submission workflow supports.

Quality Management Software

Quality Workflow Coverage

Stay Inspection-Ready Without the 2-Week Scramble

Draft 483 Responses in Hours, Not a Month

Track GxP Guidance Changes Across FDA, EMA, and PMDA

Coordinate Global Quality Activities Without the Weekly Status Calls

Quality Controls and Capacity

Maintain Audit-Ready Team Execution

Manage More Quality Work Without Growing the Team

Questions About Quality Workflows

See Quality Workflows in Assyro.